Because 2-methoxyestradiol (2-MeOE 2 ) induces and stabilizes wild-type p53 protein (wt p53) in human lung cancer cell lines posttranscriptionally, we sought to study its eects on Ad5p53-transduced lung cancer cell lines at a low multiplicity of infection (1 MOI). Treating these cells with 2-MeOE 2 resulted in superinduction of wt p53 protein expression followed by apoptosis, as shown by terminal deoxynucleotidyl transferase (TdT) staining, and upregulation of wt p53 expression, as shown by Western blot analysis. When transduced with Ad5p53 alone at 1 MOI, the cell lines grew rapidly. Moreover, adenoviral-vector-mediated p53 gene transfer followed by 2-MeOE 2 treatment caused 80% growth inhibition in the cell lines regardless of their p53 status. Thus, p53 superinduction and apoptosis after 2-MeOE 2 treatment in Ad5p53-transduced cells appears to be a unique strategy with signi®cant implications for cancer gene therapy.
Introduction
The p53 gene is the most commonly mutated gene in human cancer (Nigro et al., 1989; Takahashi et al., 1989) , and mutation in its protein often inactivates the protein's tumor suppressor function. Knowing this, many groups have tried to circumvent the loss of suppressor function by taking advantage of the fact that wild-type p53 (wt p53) is a dominant inhibitor of tumor cell growth. Expression of exogenous wt p53 alone at low copy numbers can suppress the growth of p53-mutated or p53-deleted lung cancer cell lines, but it is generally insucient to induce apoptosis (Fujiwara et al., 1994; Cai et al., 1993) . In contrast, introduction of the wt p53 gene, which induces high levels of p53 protein expression, is known to induce apoptosis in some types of tumor cell lines with deleted or mutated p53 (Yonish-Rouach et al., 1991; Shaw et al., 1992) . However, the tumors or tumor cell lines that contain wt p53 are mostly refractory to p53-mediated apoptosis.
We previously have shown that exposing some human cancer cells to micromolar levels of 2-methoxyestradiol (2-MeOE 2 ) can induce the accumulation of native wt p53 protein and cause apoptosis only in the presence of the wt p53 gene product (Mukhopadhyay and Roth, 1997) . That represented the ®rst psychological example of high levels of endogenous wt p53 being induced and in turn inducing apoptosis. In this report, we describe a unique approach to inducing apoptosis in human lung cancer cell lines, whereby cells are transduced with Ad5p53 at low MOIs and treated with 2-MeOE 2 , resulting in apoptosis irrespective of their p53 status.
Results and discussion
To determine the eect of 2-MeOE 2 on wt p53 accumulation (in terms of kinetics and dose response), H460 cells (wt p53) were incubated with dierent concentrations of 2-MeOE 2 for 48 h in culture and then analysed for p53 protein levels by Western blot analysis ( Figure 1a) . The results indicated that 5 mM 2-MeOE 2 induced high levels of wt p53 protein in this cell line. Moreover, even though 1 mM 2-MeOE 2 induced an increase in wt p53 protein levels, it had no eect on the proliferation of the H460 cells (data not shown). In addition, the 5 mM concentration of 2-MeOE 2 by itself had no eect on either cell viability or apoptosis of normal bronchial cells but did induce apoptosis in tumor cells containing wt p53. In further experiments, we studied the eect on wt p53 induction in more detail. An increase in p53 accumulation in H460 cells was noted 4 h after the addition of 5 mM 2-MeOE 2 with a maximum eect observed after 24 h. Densitometric scanning of the Western blot con®rmed induction of p53 after 4 h (Figure 1b) . In H460 cell line, apoptotic cells were noticed after 18 h of 2-MeOE 2 treatment as described earlier (Mukhopadhyay and Roth, 1997) however, it varies among dierent cell lines.
In order to know whether the 2-MeOE 2 -mediated apoptosis observed in H460 cell line was really mediated through the wt p53 protein, we used human p53-deleted H1299 lung cancer cell line for our studies. Superinduction of wt p53 was observed when Ad5p53-transduced H1299 cells (1 MOI) were treated with 2-MeOE 2 (Figure 2a ). This result suggests a novel strategy for experimental gene therapy based on the combinatorial eects of 2-MeOE 2 and Ad5p53 transduction in inducing wt p53-mediated programmed cell death. In particular, we noted that upregulation of wt p53 protein after 2-MeOE 2 treatment increased the sensitivity of tumor cells to apoptotic stimuli. This ®nding was observed in experiments in which we infected two dishes of H1299 cells for 24 h with adenoviral vector carrying a wt p53 gene under the control of the CMV promoter at MOI 1. After washing the next day with phosphatebuered saline (PBS) and feeding with fresh medium, one culture was given 5 mM 2-MeOE 2 in dimethyl sulfoxide, and the other was given only dimethyl sulfoxide (control). Treated and control cells were then incubated for another 24 h, washed in PBS, and analysed for p53 protein. As shown in Figure 2a , H1299 cells were de®cient in endogenous p53 and expressed only the ectopic protein. In contrast, wt p53 was much more strongly expressed when the cells were infected with Ad5p53 and then treated with 2-MeOE 2 (lane 3) than when infected with Ad5p53 only (lane 2). Consequently, wt p53 levels were increased in transduced, 2-MeOE 2 -treated H460 and A549 cell lines, even after 5 days (Figure 2b ). Expression of p21 protein, a target of p53, was also induced after this treatment. However, after transduction of wt p53 into the H322 cell line, which expresses mutant p53, the induction in p53 protein level was not very clear from the Western blot analysis because the mutated p53 level was intrinsically very high ( Figure 2b ). Time-course experiments further demonstrated that the ectopic expression of wt p53 protein in Ad5p53-infected H1299 cells stabilized after 2-MeOE 2 treatment (data not shown), similar to the case in 2-MeOE 2 -treated H460 cells as reported earlier (Mukhopadhyay and Roth, 1997) .
The synergistic eect of Ad5p53 and 2-MeOE 2 on tumor cell growth was examined in four human lung cancer cell lines that diered in p53 status but were all transduced with Ad5p53: H1299 (p53 deleted), H322 (p53 mutated), H460 (wt p53) and A549 (wt p53). Because our initial dose-response studies indicated that 5 mM 2-MeOE 2 induced high levels of wt p53 protein expression in H460 cells without toxicity, we used this concentration for all our proliferation assays. In those assays, growing, cultured cells were trypsinized and plated (10 4 cells/well) and then infected the next day with Ad5p53 or dl312 (empty vector) at 1 MOI. Viral supernatant was then added, after which cells were incubated for 24 h, washed with PBS, fed fresh medium or incubated with medium containing 5 mM 2-MeOE 2 for 24 h, washed again, and fed fresh medium. In contrast, uninfected cells (controls) were treated with 5 mM 2-MeOE 2 for 24 h, washed with PBS, Western blot analysis of four tumor cell lines infected with 1 MOI Ad5p53 for 24 h and then further treated with 5 mM 2-MeOE 2 for 24 h. After the treatments, all cells were grown in drug-free medium for 4 days and then examined for p53 expression. The H460 and A549 cell lines express wt p53; the H322 cell line expresses mutant p53 (codon 248 mutation); the H1299 cell line has a homozygous p53 deletion. Control or treated cells were harvested, placed in 16SDS ± PAGE loading buer, and boiled for 5 min. A total of 30 mg protein/lane was then electrophoresed through a 10% denaturating polyacrylamide gel and electroblotted onto a membrane as described previously . p53 was detected immunohistochemically using an antihuman p53 monoclonal antibody (Biotechnology Inc., Santa Cruz, CA). Then, blots were either simultaneously probed or reprobed with actin monoclonal antibody as described previously . Blots were further probed with p21 WAF1/CIP1 monoclonal antibody (Pharmingen). Superinduction of wt-p53 by 2-methoxyestradiol T Mukhopadhyay and JA Roth fed fresh medium, and then subjected to a 5-day growth assay (Figure 3a) . Our experimental results indicated that d1312 had no eect in combination with 2-MeOE 2 (Figure 3b) . Meanwhile, all the other cell lines, except for H1299 cells, were quite resistant to Ad5p53-mediated growth inhibition. Dose-titration experiments showed that for 50% growth inhibition, H322, H460 and A549 cells required an eective concentration of about 100 MOI versus about 5 MOI for H1299 cells (data not shown). When the four lung cancer cell lines were transiently infected with 1 MOI Ad5p53 or d1312 for 24 h, no growth suppression was observed, regardless of p53 status. When all four lines were treated with 2-MeOE 2 alone for 24 h, the p53-mutated and deleted cells were not growth inhibited, whereas the wt p53 H460 and a b Figure 3 Cell growth assays. Approximately 10 4 cells were seeded on tissue culture plates 24 h before drug treatment or adenoviral infection. (a) Cell growth was measured in untreated controls, cells treated with 5 mM 2-MeOE 2 , and cells treated with the combination of Ad5p53 (1 MOI) and 2-MeOE 2 . Cells were also treated with an empty adenoviral vector, dl312, to serve as an internal control. (b) Growth of the vector infected cells treated with 2-MeOE 2 was assayed essentially as described above. Cell lines were infected with control adenoviral vector (1 MOI dl312, 24 h) followed by 5 mM 2-MeOE 2 treatment (24 h) and then grown in control growth medium for 5 days. The growth of control untreated versus treated cells was compared by counting the cells on day 5 as described above. Triplicate cultures were harvested at various time points, stained with crystal violet, and counted for cell number. An Ad5p53 mammalian expression vector was constructed in our laboratory as previously reported (Zhang et al., 1993) . The MOI was de®ned as the ratio of the total number of plaque-forming units used in a particular infection to the total number of cells to be infected. Adenovirus preparations were free of replication-competent adenovirus as determined by previously described techniques (Zhang et al., 1995) . Cell growth was measured in untreated controls, in cells treated with 5 mM 2-MeOE 2 , and in cells infected with Ad5p53. The cell lines used were H1299, H322, H460 and A549. Cultures were harvested at various time points, and cell numbers were counted after crystal-violet staining. Results are representative of three independent experiments; bars, s.d. A549 cells were signi®cantly so. However, a striking growth inhibition was observed in all four cell lines when the Ad5p53-transduced cells (1 MOI, 24 h) were treated with 2-MeOE 2 for 24 h and were grown in normal medium for a 5-day growth assay. In brief, apoptotic cell death varied among cell lines after this combination treatment. The H460 cells (containing wt p53) showed 35% apoptotic cells, whereas the H322 cells (containing mutated p53) showed 25% apoptotic cells 5 days after combination treatment, as revealed by terminal deoxynucleotidal transferase (TDT) staining analysis via¯uorescence-activated cell sorting (FACS).
Thus, neither treatment alone caused growth inhibition in the p53-mutated or p53-deleted cell lines, whereas together they did. Therefore, our ®ndings suggest that transfecting small amounts of Ad5p53 will induce ecient p53-mediated killing of tumor cells in the presence of p53 superinduction by 2-MeOE 2 .
Because Ad5p53-transduced cells rapidly underwent apoptosis following 2-MeOE 2 treatment, we also investigated the mechanism of cell death in our chosen cell lines using the TUNEL assay (Figure 4) . Cultures of H1299 cells infected with 1 MOI Ad5p53 or treated with 2-MeOE 2 showed no apoptotic bodies (i.e., no TdT staining), whereas Ad5p53-transduced cells treated with 2-MeOE 2 displayed many such bodies. We reported earlier that H460 and A549 cell lines containing wt p53 undergo p53-mediated apoptosis following 2-MeOE 2 treatment by TdT-FACS analysis, but 2-MeOE 2 had no eect on the H322 cell line (Mukhopadhyay and Roth, 1997) . However, under the present strategy, we con®rmed that the H322 cell line did indeed undergo apoptosis cell death by TdT-FACS analysis when transduced with 1 MOI Ad-p53 and treated with 2-MeOE 2 ( Figure 5 ). Moreover, our results indicated that 1 MOI Adp53 could induce marginal apoptosis in the H322 cell line and that 2-MeOE 2 treatment could enhance the apoptotic activity 6 ± 8-fold, but that neither treatment alone had any signi®cant eect. These results parallel our cell proliferation data.
The synergy between transfected p53 and 2-MeOE 2 oers strong possibilities for treating cancers via gene therapy. 2-MeOE 2 appears to have several unique features. First, it is a nontoxic metabolic byproduct of estrogen present in normal human urine. Second, it causes an accumulation of wt p53 protein that is associated with apoptosis. Third, although the Figure 4 TUNEL assay of apoptotic H1299 cells. Apoptotic H1299 cells were detected by TUNEL assay as described earlier (Fujiwara et al., 1994) using biotinylated dUTP and 100 U/ml TdT enzyme in cacodylate buer. The avidin-biotin complex was detected using a Vectastain Elite kit (Vector Labs., Burlingame, CA). (a) Contro mock-transfected H1299 cells grown in normal growth medium for 48 h; (b) H1299 cells infected with 1 MOI Ad5p53 for 24 h, washed and allowed to grow for another 24 h in normal growth medium, and then processed for TUNEL assay; (c) H1299 cells infected with 1 MOI Ad5p53 for 24 h, washed, treated with 5 mm 2-MeOE 2 for another 24 h, then processed for TUNEL assay Figure 5 TdT-FACS analysis of apoptotic cells. The percentage of H322 cells showing apoptosis was measured by FACScan after TdT staining as described previously (Mukhopadhyay and Roth, 1997) . The apoptotic cells were labeled in situ with biotinylated dUTP in a reaction mixture employing exogenous TdT followed by¯uoresceinated avidin binding. H322, C, control untreated cell line (322-2ME), treated with 5 mM 2-MeOE 2 for 24 h; 322 dl312, cells transduced with 1 MOI empty adenoviral vectors for 24 h; 322-Ad-p53, cells infected with 1 MOI Ad5-p53 for 24 h; 322-Adp53-2ME, cells infected with 1 MOI Ad5-p53 (24 h) washed, and then treated with 5 mM 2-MeOE 2 for 24 h. After the appropriate treatments, all cells were grown in drug-free medium for 5 days and subjected to TdT-FACS analysis molecular basis for the preferential sensitivity of tumor cells is not understood, the 2-MeOE 2 eect is speci®c to lung cancer cells when compared with normal bronchial epithelial cells (Seegers et al., 1997; Mukhopadhyay and Roth, 1997) . 2-MeOE 2 alone can induce p53 in cancer cell lines containing endogenous wt p53, resulting in some degree of growth inhibition and apoptosis (Mukhopadhyay and Roth, 1997) .
A mutation in the p53 gene often functionally inactivates the p53 gene and contributes to malignant progression (Vogelstein and Kinzler, 1992; Levine, 1997) . Accumulation of wt p53 protein may cause the cell to enter one of two pathways: cell-cycle arrest or programmed cell death (Levine, 1997) . Though the exact mechanism through which wt p53 induces apoptosis is not clearly understood, some studies suggest that p53 is transcriptionally activated in the induction of apoptosis (Yonish-Rouach et al., 1996) , whereas others suggest not (Wagner et al., 1994) .
This report decribes a novel strategy for human gene therapy that combines an adenoviral vector for p53 with an agent that by itself, at active concentrations, is nontoxic to the cells but causes enhanced transgene expression. Indeed, 2-MeOE 2 has been shown to reduce the tumor vascularization critical for tumor growth in vivo and to be noncytotoxic to normal human skin ®broblasts even at a concentration of 100 mM (Fotis et al., 1994) . However, the mechanism whereby 2-MeOE 2 can increase wt p53 levels is not clear. To shed some light, wt p53 protein turnover in 2-MeOE 2 -treated H460 cells were thus compared with that in untreated control parental cells in a pulse-chase experiment as reported earlier (Mukhopadhyay and Roth, 1997) . Control mock-treated and 2-MeOE 2 -treated H460 cells were processed for Western blot analysis. Subsequent densitometric scanning of the Western blots indicated that p53 protein in the H460 cells treated with 5 mM 2-MeOE 2 was much more resistant to proteolytic degradation and thus more stable than that in mocktreated cells. It also appears that 2-MeOE 2 has a pleiotropic eect on cellular processes depending on cell type and cellular context. Induction of p53 protein after 2-MeOE 2 treatment correlated with increased expression of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 protein in cells expressing wt p53 (Mukhopadhyay and Roth, 1997) . A similar phenomenon has been observed in other cell types. For example, we have found in MCF-7 cells that a high level of p53 protein induction is associated with apoptosis (data not shown). An earlier report indicated that treating the estrogen-dependent MCF-7 cell line with 2-MeOE 2 caused G2/M arrest associated with depolymerization of tubulin (Tishler et al., 1995) . However, we observed no eect of 2-MeOE 2 on tubulin structure in immuno¯uorescence studies of our lung cancer cell lines (data not shown) or in A431 cells, even at concentrations of 20 mM (Attalla et al., 1996) . It has also been suggested that 2-MeOE 2 causes mitotic arrest in a leukemia cell line by inhibiting the calmodulin pathway (Attalla et al., 1996) . Yet, when lung cancer cell lines are treated with 5 mM of 2-MeOE 2 , there is no eect on the distribution of tumor cells in the dierent phases of the cell cycle (Mukhopadhyay and Roth, 1997) . These data suggest that 2-MeOE 2 acts through a separate pathway for activating p53 and subsequent p53-dependent processes.
One plausible pathway is altered phosphorylation of p53 protein isoforms, as has been suggested by twodimensional gel electrophoretic analysis of total protein after 2-MeOE 2 treatment (Maxwell et al., 1996) . Speci®c phosphorylation events generating isoforms of p53 may stabilize p53 protein levels and regulate its function in apoptosis. However, this does not rule out the possibility that increased wt p53 stability is caused by 2-MeOE 2 -induced endogenous eector molecules that may bind p53 and modulate its conformation, resulting in a more stable protein and thus altering pathways involved in p53 turnover.
When p53-negative H1299 cells are treated with 2-MeOE 2 or infected with 1 MOI Ad5p53, there appears to be little eect on cell growth. But when Ad5p53-transduced cells are treated with 2-MeOE 2 , a severalfold increase in transgene expression is followed by rapid apoptosis. This suggests that superinduction of wt p53 protein may be responsible for the induction of apoptosis. This is consistent with a recent report indicating that the level of p53 protein expression is an important determinant of apoptosis (Chen et al., 1996) . Though high doses of Ad5p53 (50 ± 100 MOI) along with 2-MeOE 2 are extremely eective in killing the lung cancer cells (*95 ± 100%; data not shown), very low doses of Ad5p53 combined with 2-MeOE 2 may be adequate to control cancer cell growth in vivo, thus avoiding viral vector toxicity at high doses. Combination treatment with Ad5p53 followed by 2-MeOE 2 therefore suggests novel strategies for p53 genereplacement approaches to cancer treatment.
